Inhibition of de novo ceramide synthesis by sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes
Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular (CV) diseases. Restoration of systemic SIRT1 may provide a novel therapeutic strategy to counteract toxic ceramide synthesis and mitigate CV complications of T2D.
Read full article (Cardiovascular Research (2024) 120, 1265–1278)